GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Intangible Assets

Albany Molecular Research (Albany Molecular Research) Intangible Assets : $407.1 Mil (As of Jun. 2017)


View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Albany Molecular Research's intangible assets for the quarter that ended in Jun. 2017 was $407.1 Mil.


Albany Molecular Research Intangible Assets Historical Data

The historical data trend for Albany Molecular Research's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Intangible Assets Chart

Albany Molecular Research Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.07 3.04 94.33 289.68 396.43

Albany Molecular Research Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 287.74 421.02 396.43 395.05 407.08

Albany Molecular Research Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Albany Molecular Research  (NAS:AMRI) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Albany Molecular Research Intangible Assets Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Albany Molecular Research (Albany Molecular Research) Business Description

Traded in Other Exchanges
N/A
Address
Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Executives
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin officer: SVP, Treasurer & CFO 26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming director C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth director, officer: President and CEO 236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson officer: SVP, Secretary & Gen Counsel MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther officer: Senior VP, Discovery Services 21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost officer: Chief Financial Officer 21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek officer: Chief Financial Officer ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines